Advertisement

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Sep
16
Today In Oncology
New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Viral Immunotherapy May Extend Survival in Advanced NSCLC After Progression on Immune Checkpoint Inhibition
Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo